Jeff Yass’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $102K | Sell |
29,789
-156,841
| -84% | -$593K | ﹤0.01% | 12486 |
|
|
2026
Q1 | $778K | Buy |
186,630
+105,189
| +129% | +$444K | ﹤0.01% | 8539 |
|
|
2025
Q4 | $224K | Buy |
81,441
+30,137
| +59% | +$86K | ﹤0.01% | 10626 |
|
|
2025
Q3 | $176K | Sell |
51,304
-65,042
| -56% | -$237K | ﹤0.01% | 11121 |
|
|
2025
Q2 | $400K | Buy |
116,346
+31,016
| +36% | +$81.9K | ﹤0.01% | 9682 |
|
|
2025
Q1 | $182K | Buy |
85,330
+58,891
| +223% | +$177K | ﹤0.01% | 11045 |
|
|
2024
Q4 | $84.3K | Buy |
26,439
+5,853
| +28% | +$47.8K | ﹤0.01% | 11442 |
|
|
2024
Q3 | $275K | Buy |
+20,586
| New | +$274K | ﹤0.01% | 9795 |
|
|
2024
Q2 | – | Sell |
-53,529
| Closed | -$637K | – | 12103 |
|
|
2024
Q1 | $637K | Buy |
+53,529
| New | +$456K | ﹤0.01% | 7927 |
|
|
2023
Q4 | – | Sell |
-1,934
| Closed | -$5.29K | – | 12407 |
|
|
2023
Q3 | $5.29K | Buy |
1,934
+287
| +17% | +$1.34K | ﹤0.01% | 11785 |
|
|
2023
Q2 | $11K | Buy |
+1,647
| New | +$10K | ﹤0.01% | 11747 |
|
|
2023
Q1 | – | Sell |
-1,935
| Closed | -$4.78K | – | 12622 |
|
|
2022
Q4 | $4.78K | Buy |
+1,935
| New | +$6.38K | ﹤0.01% | 12050 |
|
|
2022
Q3 | – | Sell |
-3,533
| Closed | -$11K | – | 13219 |
|
|
2022
Q2 | $11K | Buy |
3,533
+1,714
| +94% | +$5.24K | ﹤0.01% | 12489 |
|
|
2022
Q1 | $7K | Sell |
1,819
-14,689
| -89% | -$53.6K | ﹤0.01% | 12785 |
|
|
2021
Q4 | $64K | Buy |
+16,508
| New | +$88.1K | ﹤0.01% | 12425 |
|
|
2021
Q2 | – | Sell |
-2,534
| Closed | -$28K | – | 12589 |
|
|
2021
Q1 | $28K | Buy |
+2,534
| New | +$38.3K | ﹤0.01% | 12111 |
|
|
2020
Q3 | – | Sell |
-1,342
| Closed | -$7K | – | 10563 |
|
|
2020
Q2 | $7K | Sell |
1,342
-7,901
| -85% | -$50.8K | ﹤0.01% | 9996 |
|
|
2020
Q1 | $49K | Buy |
+9,243
| New | +$69.8K | ﹤0.01% | 9690 |
|
|
2019
Q4 | – | Sell |
-3,844
| Closed | -$12K | – | 9755 |
|
|
2019
Q3 | $12K | Buy |
3,844
+2,267
| +144% | +$8.21K | ﹤0.01% | 9998 |
|
|
2019
Q2 | $6K | Buy |
+1,577
| New | +$6.61K | ﹤0.01% | 10099 |
|
|
2018
Q4 | – | Sell |
-1,017
| Closed | -$5K | – | 8984 |
|
|
2018
Q3 | $5K | Buy |
+1,017
| New | +$5.66K | ﹤0.01% | 9063 |
|
|
2018
Q2 | – | Sell |
-32,655
| Closed | -$137K | – | 9639 |
|
|
2018
Q1 | $137K | Buy |
32,655
+19,571
| +150% | +$86.3K | ﹤0.01% | 8569 |
|
|
2017
Q4 | $52K | Buy |
13,084
+11,950
| +1,054% | +$55.7K | ﹤0.01% | 8899 |
|
|
2017
Q3 | $6K | Buy |
+1,134
| New | +$6.37K | ﹤0.01% | 8702 |
|
|
2016
Q3 | – | Sell |
-2,824
| Closed | -$25K | – | 8420 |
|
|
2016
Q2 | $25K | Buy |
+2,824
| New | +$27K | ﹤0.01% | 8354 |
|
|
2015
Q2 | – | Sell |
-1,254
| Closed | -$20K | – | 10105 |
|
|
2015
Q1 | $20K | Sell |
1,254
-835
| -40% | -$12.4K | ﹤0.01% | 9275 |
|
|
2014
Q4 | $31K | Buy |
+2,089
| New | +$33.1K | ﹤0.01% | 9445 |
|
|
2014
Q3 | – | Sell |
-1,065
| Closed | -$33K | – | 9442 |
|
|
2014
Q2 | $33K | Buy |
+1,065
| New | +$26.7K | ﹤0.01% | 9653 |
|
Other funds holding CATX
TCM
CC
APM
AAA
SSC
Jeff Yass's CATX Position: Q2 2026 in Review
Jeff Yass reduced its Perspective Therapeutics (CATX) stake by 84% in Q2 2026, selling an estimated $593K and leaving 29,789 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #12486.
Jeff Yass first reported a position in CATX in Q2 2014 and has held it in 28 quarters since. The position peaked at $778K in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.
- Jeff Yass held 29,789 shares of Perspective Therapeutics worth $102K as of Q2 2026.
- Jeff Yass sold 156,841 Perspective Therapeutics shares in Q2 2026, an estimated $593K.
- Perspective Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12486 holding.
- Jeff Yass first reported a position in Perspective Therapeutics in Q2 2014 and has held it in 28 quarters since.
- Jeff Yass's Perspective Therapeutics position peaked at $778K in Q1 2026.
- 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.